Apellis Pharmaceuticals, Inc. (APLS)

25.23 +0.26 (+1.06%) USD  |  NASDAQ  |  Dec 12, 16:00
25.23 0.00 (0.00%) After-Hours: 20:00
More

Apellis Pharmaceuticals Research and Development Expense (TTM): 297.98M for Sept. 30, 2025

Research and Development Expense (TTM) Chart

View Research and Development Expense (TTM) for APLS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
Biogen, Inc. 1.524B
Amicus Therapeutics, Inc. 142.29M
Fortress Biotech, Inc. 22.21M
Ultragenyx Pharmaceutical, Inc. 699.19M
Fulcrum Therapeutics, Inc. 51.08M